OBSV News and Press, ObsEva SA From 02/24/23

Swiss biotech ObsEva SA ( NASDAQ: OBSV ) lost ~16% pre-market Friday after announcing a major reorganization drive, including plans to delist from the Nasdaq stock exchange due to its failure to meet the minimum bid price requirement. The company focused on female reproductive hea...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – February 24, 2023 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced a s...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 19 , 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s ...

Biopharmaceutical company ObsEva ( NASDAQ: OBSV ) has demonstrated compliance with Nasdaq's minimum stockholders' equity requirement. In August, the company received a letter from the Nasdaq Stock Exchange regarding its non-compliance with the minimum stockholders' equity requirem...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 14 , 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s heal...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 9 , 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, annou...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 1 , 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN) (“ObsEva” or the “Company”), a biopharmaceutical company developing novel th...

Sale of Ebopiprant royalty and milestone license to XOMA includes upfront payment of $15 million and future milestone payments of up to $98 million The sale proceeds are expected to enable ObsEva to resolve its current over-indebtedness position and to withdraw its pending Swiss morat...

ObsEva ( NASDAQ: OBSV ) is scheduled to announce Q3 earnings results on Monday, November 7th, before market open. The consensus EPS Estimate is -$0.10 and the consensus Revenue Estimate is $2.5M (-87.6% Y/Y). Over the last 3 months, EPS estimates have seen 2 upward r...

Transition of linzagolix program to Kissei Pharmaceutical Co., Ltd. substantially complete with approximately $ 1 6.0 million savings expected from assignment of program contracts, including $ 3. 7 million of accounts payable assig...